NCT03556098View on ClinicalTrials.gov

Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 22, 2019

Primary Completion Date

February 11, 2020

Study Completion Date

February 11, 2020

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

glucose-dependent insulinotropic peptide

Infusion of GIP

DRUG

Glucose-Dependent Insulin-Releasing Hormone[3-30]

Infusion of GIP antagonist GIP\[3-30\]

DRUG

Saline Solution

Infusion of Saline

Trial Locations (1)

2900

Steno Diabetes Center Copenhagen, Clinical Metabolic Physiology, Hellerup

All Listed Sponsors
lead

Steno Diabetes Center Copenhagen

OTHER

NCT03556098 - Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes | Biotech Hunter | Biotech Hunter